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Objectives. This study assessed the long-term clinical outcome
of stenting chronic occlusions.
Background. In the Stenting in Chronic Coronary Occlusion
(SICCO) study, patients were randomized to additional stent
implantation (n 5 58) or not (n 5 59) after successful recanali-
zation and dilation of a chronic coronary occlusion. Palmaz-
Schatz stents were used with full anticoagulation. The previously
published 6-month angiographic follow-up results showed reduc-
tion of the restenosis rate from 74% to 32%.
Methods. The primary end point was the occurrence of major
adverse cardiac events (cardiac death, lesion-related acute myo-
cardial infarction, repeat lesion-related revascularization or an-
giographic documentation of reocclusion).
Results. Late clinical follow-up was obtained in all patients at
33 6 6 months. Major adverse cardiac events occurred in 14
patients (24.1%) in the stent group compared with 35 patients
(59.3%) in the percutaneous transluminal coronary angioplasty
(PTCA) group (odds ratio 0.22, 95% confidence interval 0.10 to
0.49, p 5 0.0002). Target vessel revascularization (including failed
PTCA attempts) was performed in 24% of the stent group and in
53% of the PTCA group (p 5 0.002). There were no events in the
stent group after 8 months, whereas events continued to occur in
the PTCA group. By multivariate analysis, allocation to the PTCA
group, left anterior descending coronary artery lesion and lesion
length were significantly related to the development of major
adverse cardiac events.
Conclusions. These data demonstrate the long-term safety and
clinical benefit of stenting recanalized chronic occlusions. There is
a continued risk of late clinical events related to nonstented
lesions. Implantation of an intracoronary stent should therefore
be considered after successful opening of a chronic coronary
occlusion.
(J Am Coll Cardiol 1998;32:305–10)
©1998 by the American College of Cardiology
Although 60% to 70% of chronic coronary occlusions can be
successfully opened by percutaneous transluminal coronary
angioplasty (PTCA) (1), concerns have been raised about the
usefulness of this approach in view of the high restenosis rate
and possible complications (2–6).
As recently shown in the Stenting in Chronic Coronary
Occlusion (SICCO) study (7) that stenting improves the an-
giographic outcome after PTCA of chronic coronary occlu-
sions, with a reduction in the 6-month restenosis rate from
74% to 32% in the group with additional stent implantation
compared with the group treated with angioplasty only. Several
studies (8–10) indicate that the patency of the treated vessel is
important for the long-term clinical outcome in these patients
However, there are few reports on the long-term clinical
outcome after stenting of chronic coronary occlusions. Accord-
ingly, we wanted to investigate whether the initial advantage
observed in the stent group in the SICCO trial at the 6-month
angiographic follow-up was maintained during a longer
follow-up of further clinical events.
Methods
The SICCO study was a randomized, controlled, multi-
center trial of 117 patients investigating the effect of additional
intracoronary stenting after successful angioplasty of chronic
coronary occlusions. Patients were recruited between March
1994 and May 1995. The inclusion criteria for the SICCO study
are shown in Table 1. The current study reports the long-term
clinical follow-up results of this patient cohort.
Interventional procedure and randomization. Written in-
formed consent was obtained before start of the procedure
from prospective study participants. Provided that they had a
fully satisfactory PTCA result, patients were randomized to a
control group (n 5 59), with no further invasive treatment, or
to additional implantation (n 5 58) of Palmaz-Schatz stents
(Johnson & Johnson Interventional Systems). Patients with
stenting were given full anticoagulation with warfarin for 3
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months (7). Quantitative coronary angiography was performed
before randomization, at the end the procedure and at
6-month follow-up, as previously described (7,11). Reocclusion
was defined as a minimal lumen diameter (MLD) of zero and
reappearance of occlusion (Thrombolysis in Myocardial Infarc-
tion [TIMI] flow grade 0 or 1) at the lesion site. Restenosis was
defined as a diameter stenosis (DS) $50% at angiographic
follow-up.
Long-term follow-up and clinical end points. According to
the protocol, at least 2 years after inclusion the patients were
contacted by questionnaire or telephone interview, or both, to
check for further events after the 6-month follow-up examina-
tion. Anginal symptoms were characterized according to the
Canadian Cardiovascular Society classification (12) and were
also assessed by a questionnaire (13). Adjunctive information
regarding clinical events was obtained from the referring
hospital or physician. Event-free survival was calculated from
the date of the procedure to the clinical event or the time of
the last follow-up contact.
The primary end point of the study was the occurrence of
major adverse cardiac events, defined as cardiac death, lesion-
related acute myocardial infarction (AMI), repeat lesion-
related angioplasty, bypass surgery involving the treated seg-
ment or angiographic documentation of reocclusion in
nonrevascularized patients. When more than one clinical end
point occurred in a patient, the event occurring first was
considered for the event-free survival analysis. For composite
analysis, all events were considered. Death was considered to
be cardiac related, unless proven otherwise.
Patients were considered for further revascularization if
they had angina or inducible ischemia related to a coronary
lesion, or both. Target vessel revascularization (TVR) was
defined as any revascularization that involved the target vessel.
Target lesion revascularization (TLR) was defined as a success-
ful revascularization procedure (PTCA or surgical bypass)
driven by a stenosis reappearing at the treated site (including
5 mm proximal and distal to the lesion borders). Urgent
revascularization was defined as revascularization occurring
within 72 h after onset of severe symptoms. AMI was defined
as a clinical episode of prolonged chest pain suggestive of acute
myocardial infarction and an increase in serum cardiac enzyme
levels to at least twice the upper normal limit, or the appear-
ance of one or more new pathologic Q waves in patients not
admitted to the hospital.
Statistical methods. All analyses were performed on an
intention to treat principle. Continuous variables are presented
as mean 6 SD or median (range) and categoric variables as
number (percent). Differences between groups were evaluated
using the Student t test or the Mann-Whitney U test for
continuous variables and by chi-square analysis with the Fisher
exact test and odds ratio with 95% confidence intervals for
categoric variables. The contribution of clinical, angiographic
and procedural variables to the categoric outcome variables of
major adverse cardiac events and TVR were evaluated with
logistic regression analysis. Continuous variables were checked
for linearity in logit by the Box-Tidwell test. The contribution
of each variable was first assessed independently by univariate
analysis. Variables with a p value #0.3 were then entered
stepwise into an unconditional logistic regression model. A
manual forward selection was performed adding to the model
only the factor giving the largest significant difference in log
likelihood ratio at each step. The results of logistic regression
analysis were given as the odds ratio with 95% confidence
interval. The Kaplan-Meier estimate was used to generate
survival and event-free curves, and the log-rank test was used
to compare the two treatment groups. All reported p values
were two-tailed, and a p value ,0.05 was considered statisti-
cally significant. The computer program used was Systat 7.0
(SPSS, Inc.).
Results
Clinical and angiographic baseline characteristics, as well as
immediate procedural and 6-month angiographic results, have
been published previously (7). Stent implantation was unsuc-
cessful in one patient (who later developed restenosis and
underwent repeat PTCA). There were no statistical significant
differences between the two groups at baseline (Table 2),
whereas the angiographic 6-month restenosis rate was 32% in
the stent group and 74% in the PTCA group odds ratio [OR]
0.165, 95% confidence interval (CI) 0.07 to 0.37, p , 0.001)
(Table 3). Angiographic follow-up was obtained in 97% of
patients.
Abbreviations and Acronyms
AMI 5 acute myocardial infarction
CI 5 confidence interval
DS 5 diameter stenosis
LAD 5 left anterior descending coronary artery
MLD 5 minimal lumen diameter
OR 5 odds ratio
PTCA 5 percutaneous transluminal coronary angioplasty
SICCO 5 Stenting in Chronic Coronary Occlusion
TLR 5 target lesion revascularization
TVR 5 target vessel revascularization
Table 1. Selection criteria in SICCO Study
Clinical exclusion criteria
Age ,18 yr
Duration of occlusion ,2 weeks
Participation in other clinical trial
Unable to attend proposed 6-month follow-up
Anticoagulation not tolerated
Angiographic exclusion criteria
Vessel diameter ,2.5 mm
Complex anatomy making successful stent deployment unlikely
Major flow-limiting dissection or recoil .50%
Previously dilated lesions
Angiographic indication of thrombus
Poor distal runoff
SICCO 5 Stenting in Chronic Coronary Occlusion.
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Major adverse clinical events. Late clinical follow-up was
obtained in all patients at 33 6 6 months, with $28 months of
follow-up data available for 94% of patients. The follow-up
time in surviving patients was 34 6 5 months (range 25 to 43).
A major adverse clinical event occurred in 14 patients (24.1%)
in the stent group compared with 35 in the PTCA group
(59.3%) (OR 0.22, 95% CI 0.10 to 0.49, p 5 0.0002). Details of
clinical events are shown in Table 3. The event-free survival
curves of the two study groups are depicted in Figure 1. There
were no significant differences between the two groups with
respect to angina pectoris class, angina score or use of cardio-
vascular medications (Table 4).
Death and myocardial infarction. There was one cardiac
death during the follow-up period. This was a sudden, unex-
pected death 21 months after PTCA without stenting of the left
anterior descending coronary artery (LAD). At angiography
after 6 months, 62% DS was found, but this lesion was not
redilated because symptoms were minimal. Three patients
(one in the stent group and two in the PTCA group) died of
colon cancer. Survival for the whole study cohort was thus 97%
after 24 months.
A lesion-related uncomplicated inferior myocardial infarc-
tion occurred due to occlusion of the right coronary artery 12
days after stenting. There were two cases of AMI related to
lesions in other vessels. These occurred in two patients in the
PTCA group who experienced an inferior myocardial infarc-
tion .30 months after PTCA of LAD occlusions. Both patients
had an angiographically documented new occlusion of the right
coronary artery. According to our protocol, these two cases
were not counted as a major adverse cardiac event.
Figure 1. Survival without major adverse clinical events (death, AMI,
TVR, reocclusion). Solid line 5 stent group; dashed line 5 PTCA
group.







Age (yr) 57.2 6 9.4 58.4 6 12.0
Women 20% 16%
Occlusion length (mm) 17.6 6 11.8 17.3 6 8.2
CCS angina class III/IV 76% 78%
Multivessel disease 37.3% 43.1%
Estimated duration of occlusion (mo.) 4.9 (1–164) 4.6 (0.5–60)
Occluded vessel (LAD/LCx/RCA) 26/9/24 24/4/30
MLD at randomization (mm) 2.12 6 0.58 2.22 6 0.49
RD at randomization 3.17 6 0.54 3.15 6 0.49
% DS at randomization 33.5 6 10.4 29.8 6 12.4
MLD at 6-mo follow-up (mm) (n 5 114) 1.11 6 0.78 1.92 6 0.95
DS at 6-mo follow-up (n 5 114) 66.4 6 24.3 44.6 6 26.1
6-mo restenosis rate (including reocclusions)
(n 5 114)
73.7% 31.6%
Data presented are mean value 6 SD, number or percent of patients of
median (range). CCS 5 Canadian Cardiovascular Society; DS 5 diameter
stenosis; LAD 5 left anterior descending coronary artery; LCx 5 Left circumflex
coronary artery; MLD 5 minimal lumen diameter; PTCA 5 percutaneous
transluminal coronary angioplasty; RCA 5 right coronary artery; RD 5 refer-
ence diameter.
Table 3. Clinical Events
Event
Time Period













Death 0 0 0 0 3 1
Urgent revascularization 2 2 2 2 2 2
AMI related to target vessel 0 1 0 1 0 1
AMI related to other vessel 0 0 0 0 2 0
PTCA of target site 2 1 20 10 25 10
PTCA of other vessel 0 0 3 1 5 2
CABG 0 1 3 5 4 5
TLR 2 2 21 11 28 11
TVR* 2 2 23 12 31 14
MACE 2 3 27 12 35 14
*Including two patients with failed attempts to revascularize a reocclusion in each group. Data presented are number
of patients. AMI 5 acute myocardial infarction; CABG 5 coronary artery bypass graft surgery; MACE 5 major adverse
clinical event (death, AMI, TVR, reocclusion); PTCA 5 percutaneous transluminal coronary angioplasty; TLR 5 target
lesion revascularization; TVR 5 target vessel revascularization.
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TLR and TVR. Successful TLR was performed in 11
patients (19.0%) in the stent group and in 28 patients (47.5%)
in the PTCA group (OR 0.26, 95% CI 0.11 to 0.61, p 5 0.002).
Furthermore, there were two patients in each group in whom
an attempt to revascularize a reoccluded vessel by angioplasty
failed and in whom operation was not recommended. In
addition there were two cases of TVR without lesion recur-
rence. One patient in the stent group had occlusion of the
LAD distal to the stented lesion and underwent bypass surgery
24 days after the index revascularization with an open stent
preoperatively. Furthermore, a patient in the PTCA group
(with a 40% lesion DS at angiographic follow-up) was treated
for a subtotal stenosis of a marginal branch departing from the
initial occlusion site in the right coronary artery.
Thus, TVR was attempted in 14 patients (24.1%) in the
stent group and in 31 patients (52.5%) in the PTCA group (OR
0.27, 95% CI 0.12 to 0.64, p 5 0.002). Details of the revascu-
larization procedures are shown in Table 3, and the evolution
of TVR is depicted in Figure 2. Of the 18 patients in the stent
group with angiographic restenosis, TVR was performed in 11
(61%) compared with 28 (67%) of the 42 patients in the PTCA
group with angiographic restenosis (p 5 0.8). Of the seven
patients in the stent group who had reocclusion of the treated
artery at follow-up angiography, two (29%) did not undergo
revascularization. Correspondingly, in the PTCA group 4
(27%) of the 15 patients with a reoccluded artery did not
undergo revascularization. No further clinical events occurred
in the patients with nonrevascularized reocclusion.
In the stent group there were five patients with a moderate
restenosis (not reocclusion) who did not undergo revascular-
ization because symptoms were minimal. No clinical event
occurred in any of these patients. In the PTCA group there
were 12 patients with nonocclusive restenosis in whom revas-
cularization was deferred because of minimal symptoms. Be-
sides the patient who died after 21 months, increasing clinical
symptoms developed in three of these patients, resulting in late
repeat PTCA (after 14, 19 and 22 months, respectively). Thus,
late clinical events occurred in 33% of patients with untreated
moderate restenosis in the PTCA group compared with none
in the stent group (p 5 0.3).
Subgroup analysis. The frequency of major adverse car-
diac events was 55% in LAD lesions, 38% in left circumflex
coronary artery lesions and 31% in right coronary artery
lesions (Pearson chi-square 5 0.06). There was no significant
excess of major adverse cardiac events in diabetic compared
with nondiabetic patients (50% vs. 41%), in patients with a
target vessel $3 or ,3 mm (39% vs. 46%) or in patients with
an occlusion age $3 or ,3 months (42 vs. 50%).
The use of lipid-lowering drugs was infrequent (19%) at the
start of the study and rose to 52% at long-term follow-up.
There was no significant difference between the study groups
with respect to the use of lipid-lowering drugs at follow-up
(55% and 49% in the PTCA and stent groups, respectively, p 5
0.6), nor was there any difference in the rate of major adverse
cardiac events among those with and without use of lipid-
lowering drugs (44% and 38%, respectively, p 5 0.5).
Multivariate analysis. As shown by Table 5, allocation to
PTCA treatment as opposed to additional stent implantation
was associated with a fivefold increase in the risk of a clinical
event. Other significant predictors for a clinical event were
LAD lesion (threefold increase) and lesion length (4% in-
Figure 2. Target vessel revascularization. Solid line 5 stent group;
dashed line 5 PTCA group.











Score treatment satisfaction 85 6 26 88 6 18
Score disease perception 74 6 25 74 6 20
Score angina frequency 88 6 18 84 6 22
Score physical limitation 86 6 17 85 6 19
,2 tables of NTG used last week 86.4% 89.7%
Beta-blocker use 51.0% 45.3%
Ca antagonist use 25.5% 17.0%
Long-term nitrate use 15.7% 5.7%
Statin 54.9% 49.1%
*p 5 NS for all comparisons. Data presented are mean value 6 SD or
percent of patients. Ca 5 calcium; CCS 5 Canadian Cardiovascular Society;
NTG 5 nitroglycerin.
Table 5. Predictors for Occurrence of Major Adverse
Cardiac Events*
Predictor OR (95% CI)
Multivariate
p Value
Randomized to stent treatment 0.20 (0.09–0.47) 0.0002
LAD lesion 2.97 (1.28–6.88) 0.01
Lesion length (mm) 1.04 (1.0–1.09) 0.05
*Diameter stenosis ,30% at randomization and presence of multivessel
disease had univariate p values ,0.3 but were not significant in the logistic
regression model. The logit model using stenting, left anterior descending
coronary artery (LAD) and lesion length as independent variables for prediction
of major adverse cardiac events (death, AMI, TVR, occlusion) had a McFadden
rho-square value of 0.16, with a sensitivity of 0.54 and a specificity of 0.67. CI 5
confidence interval; OR 5 odds ratio.
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crease for each millimeter over the mean value of 17.5 mm).
DS at randomization did not reach significance (OR 1.03, 95%
CI 0.99 to 1.07, p 5 0.17) when included in the model.
Discussion
Although the first intracoronary stents were implanted .10
years ago (14), the long-time safety of these intracoronary
devices has only recently been assessed (15–20) and only in
previously nonoccluded arteries. There seems to be few clinical
events and no further lumen derangement after the initial rise
of in-stent restenosis within the first 4 to 8 months (21,22). The
present study of the 117 patients with a recanalized chronic
occlusion enrolled in the SICCO study assessed the question of
whether the superior 6-month angiographic outcome in the
stent group would give rise to a long-term clinical benefit. We
found that the difference between the two groups was main-
tained for a period of at least 2 years, with a paucity of late
events in the stent group but a gradual increase in clinical
events in the PTCA group.
The present study indicates that patients who are treated
for a chronic coronary occlusion with additional stent implan-
tation after successful angioplasty have a good prognosis with
respect to further lesion-related clinical events. The flat curves
after the initial 6 to 8 months in stented chronic occlusions
(Figures 1 and 2) are reassuring and indicate that even in
chronic occlusions stent implantation seems to palliate the
treated segment once the initial hurdles of subacute thrombo-
sis and in-stent restenosis have been passed. After 2 years, 76%
of patients in the stent group were event free compared with
41% who had been treated with PTCA only. The current study
is thus in accordance with previous studies on long-term
follow-up after stent implantation (15–20), although the le-
sions in these previous reports were generally short stenoses in
large vessels.
Most studies on restenosis after PTCA of nonoccluded
lesions conclude that the process of restenosis usually occurs
within the first 6 months. There are even some studies suggest-
ing the possibility of light regression in moderate restenotic
lesions (23,24). However, chronic coronary occlusions have an
overall larger tendency to develop restenosis than discrete
lesions (1,6) and it is not unusual for restenosis to develop .6
months after the initial PTCA (25,26).
One intriguing finding of the present study was that clinical
events continued to occur in the PTCA group long after
revascularization induced by the 6-month clinical and angio-
graphic follow-up (Fig. 1 and 2). Because prevention of late
vessel remodeling and contraction is the main effect whereby
stents reduce restenosis (27,28), it is possible that the contin-
ued increase in events in the PTCA group compared with the
stent group was caused by continued late vessel remodeling
and contraction.
As shown in Figures 1 and 2, the two curves separate only
after the follow-up examination at ;6 months. This is not
unexpected because patients with recurrent symptoms were
generally not referred for unscheduled early angiography as
long as they were scheduled for 6-month control angiography
free of charge. As reported in the primary publication (7), 57%
of stent group patients were free of angina at follow-up
compared with 24% of patients in the PTCA group. The
revascularizations performed after the control examination
were thus the results of a judgment taking into account both
clinical and angiographic data. The proportion of patients with
angiographic restenosis who underwent revascularization was
the same in both groups. The difference in late events was
probably not related to the use of lipid-lowering drugs because
this was similar in both groups.
We did not find any significant difference between the two
treatment groups with respect to the clinical status, angina
score or use of cardiovascular medications, possibly because of
the greater extent of revascularization in the PTCA group.
Predictors for occurrence of clinical events (Table 5).
Besides the strong effect of stent implantation in preventing
clinical events, we also found treatment of LAD lesions and
lesion length to be significant predictors for clinical events in
the multivariate model. This finding in accordance with other
studies (25,29). Neither MLD nor DS at randomization
reached statistical significance, which may be an argument
against provisional stenting (30) of chronic occlusions. How-
ever, the relatively small sample size of the current study may
give rise to type II errors in subgroup analyses.
Study limitations. According to the protocol, we random-
ized only patients with an acceptable PTCA result after first
having excluded patients with occlusions ,2 weeks in duration,
patients with vascular anatomy judged unfavorable for stenting
and patients who needed stenting because of severe dissection
or recoil. The results might thus be different in a less selected
patient cohort. Despite the limited sample size of our study, we
had 97% 6-month angiographic follow-up data and 100%
clinical long-term follow-up data. Our results should therefore
be applicable to most successfully recanalized chronic occlu-
sions when stenting is considered an option and not unavoid-
able because of severe dissection or recoil. The introduction of
more patent antiplatelet regimens have now nearly abolished
subacute stent occlusions. It is thus possible that the difference
between the two groups might have been more pronounced
had the study been repeated today.
Conclusions and recommendations. The long-term data
from the SICCO study indicate that intracoronary stenting of
chronic occlusions is associated with few clinical problems after
the first 6 to 8 months, but there seems to be a continued risk
of clinical event in patients treated with angioplasty only.
Whenever feasible, we therefore recommend intracoronary
stenting after the successful opening of a chronic coronary
occlusion.
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